» Articles » PMID: 33843668

Evaluation of SAMP8 Mice As a Model for Sleep-Wake and Rhythm Disturbances Associated with Alzheimer's Disease: Impact of Treatment with the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2021 Apr 12
PMID 33843668
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Many patients with Alzheimer's disease (AD) display circadian rhythm and sleep-wake disturbances. However, few mouse AD models exhibit these disturbances. Lemborexant, a dual orexin receptor antagonist, is under development for treating circadian rhythm disorders in dementia.

Objective: Evaluation of senescence-accelerated mouse prone-8 (SAMP8) mice as a model for sleep-wake and rhythm disturbances in AD and the effect of lemborexant by assessing sleep-wake/diurnal rhythm behavior.

Methods: SAMP8 and control senescence-accelerated mouse resistant-1 (SAMR1) mice received vehicle or lemborexant at light onset; plasma lemborexant and diurnal cerebrospinal fluid (CSF) orexin concentrations were assessed. Sleep-wake behavior and running wheel activity were evaluated.

Results: Plasma lemborexant concentrations were similar between strains. The peak/nadir timing of CSF orexin concentrations were approximately opposite between strains. During lights-on, SAMP8 mice showed less non-rapid eye movement (non-REM) and REM sleep than SAMR1 mice. Lemborexant treatment normalized wakefulness/non-REM sleep in SAMP8 mice. During lights-off, lemborexant-treated SAMR1 mice showed increased non-REM sleep; lemborexant-treated SAMP8 mice displayed increased wakefulness. SAMP8 mice showed differences in electroencephalogram architecture versus SAMR1 mice. SAMP8 mice exhibited more running wheel activity during lights-on. Lemborexant treatment reduced activity during lights-on and increased activity in the latter half of lights-off, demonstrating a corrective effect on overall diurnal rhythm. Lemborexant delayed the acrophase of activity in both strains by approximately 1 hour.

Conclusion: SAMP8 mice display several aspects of sleep-wake and rhythm disturbances in AD, notably mistimed activity. These findings provide some preclinical rationale for evaluating lemborexant in patients with AD who experience sleep-wake and rhythm disturbances.

Citing Articles

Exogenous Nucleotides Mitigate Cardiac Aging in SAMP8 Mice by Modulating Energy Metabolism Through AMPK Pathway.

Wu Y, Liu R, Wei C, Wang X, Wu X, Li Y Nutrients. 2024; 16(22).

PMID: 39599637 PMC: 11597617. DOI: 10.3390/nu16223851.


Circadian rhythm disruption and retinal dysfunction: a bidirectional link in Alzheimer's disease?.

Carrero L, Antequera D, Municio C, Carro E Neural Regen Res. 2024; 19(9):1967-1972.

PMID: 38227523 PMC: 11040320. DOI: 10.4103/1673-5374.390962.


Exogenous Nucleotides Ameliorate Age-Related Decline in Testosterone in Male Senescence-Accelerated Mouse Prone-8 (SAMP8) Mice by Modulating the Local Renin-Angiotensin System Antioxidant Pathway.

Chen Q, Liu R, Wei C, Wang X, Wu X, Fan R Nutrients. 2023; 15(24).

PMID: 38140389 PMC: 10745527. DOI: 10.3390/nu15245130.


Diurnal Characteristics of the Orexin System Genes and Its Effects on Pathology at Early Stage in 3xTg-AD Mice.

Yin J, Tuo C, Yu K, Hu X, Fan Y, Wu M Neuromolecular Med. 2023; 25(4):632-643.

PMID: 37843792 DOI: 10.1007/s12017-023-08767-w.


Progressive sleep disturbance in various transgenic mouse models of Alzheimer's disease.

Drew V, Wang C, Kim T Front Aging Neurosci. 2023; 15:1119810.

PMID: 37273656 PMC: 10235623. DOI: 10.3389/fnagi.2023.1119810.


References
1.
Beuckmann C, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H . In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. J Pharmacol Exp Ther. 2017; 362(2):287-295. DOI: 10.1124/jpet.117.241422. View

2.
Oh J, Eser R, Ehrenberg A, Morales D, Petersen C, Kudlacek J . Profound degeneration of wake-promoting neurons in Alzheimer's disease. Alzheimers Dement. 2019; 15(10):1253-1263. PMC: 6801040. DOI: 10.1016/j.jalz.2019.06.3916. View

3.
Sheehan P, Musiek E . Evaluating Circadian Dysfunction in Mouse Models of Alzheimer's Disease: Where Do We Stand?. Front Neurosci. 2020; 14:703. PMC: 7358444. DOI: 10.3389/fnins.2020.00703. View

4.
Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K . Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med. 2017; 13(11):1289-1299. PMC: 5656478. DOI: 10.5664/jcsm.6800. View

5.
Moline M, Zammit G, Cheng J, Perdomo C, Kumar D, Mayleben D . Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder. J Clin Sleep Med. 2021; 17(6):1167-1174. PMC: 8314653. DOI: 10.5664/jcsm.9150. View